MagPortal.com   Clustify - document clustering
 Home  |  Newsletter  |  My Articles  |  My Account  |  Help 
Similar Articles
Chemistry World
January 20, 2010
Phil Taylor
Screw tightens on pay-for-delay drug deals Scrutiny of the tactics used by pharmaceutical companies to delay the entry of generics onto the market is rising on both sides of the Atlantic amid claims that the practice is costing consumers billions every year. mark for My Articles similar articles
The Motley Fool
January 25, 2010
Brian Orelli
Pay-for-Delay Is Under the Spotlight It helps each side, but governments aren't thrilled with the idea. mark for My Articles similar articles
The Motley Fool
June 25, 2009
Brian Orelli
Loss of a Settlement Option Earlier this month the Federal Trade Commission came out with a report arguing for limited patent protection for drugs made by biotech companies. Now it's ratcheting up its complaints about pharmaceutical and generic-drug companies as well. mark for My Articles similar articles
Chemistry World
July 10, 2009
Sarah Houlton
Branded drugs' competition-free days numbered Authorities in the US and Europe are to look carefully at the tactics pharmaceutical firms use to delay competition from generic versions of their branded drugs. mark for My Articles similar articles
The Motley Fool
June 26, 2006
Stephen D. Simpson
Is Novartis the Future of Generics? Merck's recent pricing action might just be the beginning of the end of generics as we know them. Investors, take note. mark for My Articles similar articles
Chemistry World
November 28, 2008
Matt Wilkinson
EU claims pharma delaying tactics cost 3 billion euros Pharmaceutical manufacturers have been criticised by the EU competition commission for slowing the entry of generic medicines to the market. mark for My Articles similar articles
The Motley Fool
October 8, 2007
Brian Orelli
New FDA Regulations for Drugmakers To deal with a growing backlog of pending applications, the FDA plans to stop its first-come, first-served system. mark for My Articles similar articles
The Motley Fool
February 28, 2008
Brian Lawler
Benefiting From 2008's Generic Drugs While drug companies scramble to make up for lost revenue as their products are hit with patent expirations, other companies will benefit from the patent losses. Take a look at some winners and losers of drugs going off patent this year. mark for My Articles similar articles
Knowledge@Wharton Drug Companies and the Patent Game: Fair Play or Foul? Is legal maneuvering a legitimate attempt by the big pharmaceutical companies to recover the huge costs of developing new drugs? Or are the brand-name firms inappropriately gaming the system for their own benefit, to the detriment of consumers and insurance companies? mark for My Articles similar articles
The Motley Fool
March 7, 2007
Rich Duprey
Eisai Courts Danger The start of a patent-infringement trial sets the stage for the Japanese pharmaceutical's loss of protection on a major drug. mark for My Articles similar articles
Chemistry World
April 2, 2007
European Generics Suppliers Hit Generics drug manufacturers have lost a slice of their market with the reinstatement of a European patent covering Merck's multi-billion-dollar osteoporosis drug, Fosamax. mark for My Articles similar articles
The Motley Fool
September 9, 2010
Jim Mueller
Today's Buy Opportunity: Teva Pharmaceutical Take advantage of this growing generic-drug maker. mark for My Articles similar articles
The Motley Fool
December 29, 2006
Brian Lawler
Lilly's Patents Stay in Bloom Even with upcoming patent expiries, Lilly isn't in nearly the same desperate situation that some of its large-cap pharma peers will be dealing with in the upcoming years. Investors, take note. mark for My Articles similar articles
Pharmaceutical Executive
August 1, 2005
Jill Wechsler
Washington Report: Treating Patents It may seem unusual that a court ruling challenging patent protections is considered a victory for Big Pharma. But the decision was supported by pharmaceutical companies, along with the Justice Department, as a way to spur biomedical research and new-drug development. mark for My Articles similar articles
The Motley Fool
November 27, 2006
Brian Lawler
Teva and Pfizer Make Up The companies decide to play nice over generic versions of two of Pfizer's drugs. mark for My Articles similar articles
The Motley Fool
January 31, 2008
Brian Orelli
Wyeth Calls Teva's Bluff Wyeth launches a generic version of its own heartburn drug. mark for My Articles similar articles
The Motley Fool
December 19, 2005
Stephen D. Simpson
Pfizer Wins, a Sector Rejoices The pharmaceutical dodges a bullet and investors find renewed enthusiasm for big-cap pharma. mark for My Articles similar articles
Chemistry World
May 2006
Bea Perks
Editorial: Generics in the Dock The manufacturers of generic medicines in the U.K. must work harder to guard their good reputation. Or perhaps, manufacturers of generic medicines must work harder to counter their bad reputation. mark for My Articles similar articles
Pharmaceutical Executive
May 1, 2011
Stan Bernard
Competition 2.0: Brands vs. Generics Innovator and generics companies are colliding as they invade each other's turf. mark for My Articles similar articles
The Motley Fool
April 25, 2006
Brian Gorman
Pharma Plays With Fire Drugmakers' short-term gain could lead to long-term pain. mark for My Articles similar articles
The Motley Fool
March 13, 2008
Stephen Albainy-Jenei
Pfizer's Celebrex Aches and Pains The Court of Appeals for the Federal Circuit upholds a lower court's ruling that found Teva Pharmaceutical had infringed two of Pfizer's patents for Celebrex. mark for My Articles similar articles
The Motley Fool
July 30, 2007
Brian Orelli
Is Par Pharmaceutical Settling for Less? The generic drugmaker avoids going to court in some recent cases. Patent lawyers are the lifeblood of a generic drugmaker, and investors should want them to act as aggressively as possible so that Par can expand its product line. mark for My Articles similar articles
Bio-IT World
November 2005
Patrick R. Scanlon
Patent Term Extension Primer U.S. patent law includes provisions for extending the patent term of medical devices and pharmaceuticals in instances when lengthy FDA approval is taking place during the term. mark for My Articles similar articles
The Motley Fool
April 22, 2011
Sean Williams
Pharma's Most Perilous Pipelines Patent expirations expose weaknesses for these Wall Street darlings. mark for My Articles similar articles
BusinessWeek
April 18, 2005
Manjeet Kripalani
India: Bigger Pharma Tougher patent protection laws are spurring rapid growth in new drug research across India. mark for My Articles similar articles
Chemistry World
May 8, 2015
Matthew Gunther
Court rejects Spain's challenge to EU patent reform The European Court of Justice has dismissed a legal challenge by Spain to block the introduction of a single patent system in Europe. mark for My Articles similar articles
The Motley Fool
January 18, 2008
Brian Lawler
Wrong-Way Regulators in Europe European Union regulators raided operations of multiple large pharmaceutical companies looking for antitrust and anticompetitive actions in both the branded and generic sectors. They're looking in the wrong places. mark for My Articles similar articles
Chemistry World
May 21, 2009
Matt Wilkinson
Big Pharma set for generics boost Pharmaceutical firms have been rushing to ensure they minimize their losses by expanding their generics businesses and reach into emerging markets. mark for My Articles similar articles
The Motley Fool
December 12, 2005
Rich Duprey
Patent? What Patent? Japanese drug firm Eisai sues Teva over a patented Alzheimer's treatment. Investors, take note. mark for My Articles similar articles
Managed Care
September 2006
Payers, Consumers Benefit as Patents Expire The generic drug market seems ready to explode, according to reports from IMS Health and the Generic Pharmaceuticals Association. mark for My Articles similar articles
BusinessWeek
June 24, 2010
Bliss & Decker
Ending the Silence of Generic Drugmakers The FTC says drugmakers are paying generic rivals not to compete. mark for My Articles similar articles
Pharmaceutical Executive
April 1, 2014
Whatever Happened To Faster Reimbursement For Generics In Europe? The plan to accelerate generic pricing and reimbursement has become another tragic European casualty. mark for My Articles similar articles
The Motley Fool
June 22, 2006
Stephen D. Simpson
Merck Goes on the Attack Predator becomes prey in this latest twist in the generics game. Given how much the markets hate uncertainty, that could mean that big generic drug companies might go on sale for patient long-term investors. mark for My Articles similar articles
The Motley Fool
October 18, 2010
Brian Orelli
Pfizer Flexes Its Generic Muscles The pharma giant moves farther into generic drugs. mark for My Articles similar articles
Managed Care
September 2007
Martin Sipkoff
Patent Law Rulings Work in Favor of Generics Thanks to recent Supreme Court rulings, manufacturers of generic drugs are in a good position to continue expansion of their market share. mark for My Articles similar articles
The Motley Fool
December 3, 2008
Brian Orelli
High-Margin Generic Drugmakers -- An Oxymoron? The big profits come when a generic-drug maker doesn't have any competition. mark for My Articles similar articles
CIO
January 1, 2003
Christopher Koch
Patently Stupid? It's not clear at the start of 2003 whether the software patent frenzy will cause innovation to flower or be trampled. mark for My Articles similar articles
The Motley Fool
July 14, 2008
Brian Orelli
Teva Gets a Taste of Its Own Medicine Momenta Pharmaceuticals and Novartis are challenging the patents on Teva Pharmaceutical's blockbuster multiple sclerosis drug Copaxone. mark for My Articles similar articles
The Motley Fool
February 23, 2007
Rich Duprey
Foolish Forecast: Barr Labs Resets Bar The pharmaceutical is set to release fourth-quarter 2006 financial results. Investors, here is what you can expect to see. mark for My Articles similar articles
Pharmaceutical Executive
September 1, 2012
Jill Wechsler
Costs, Coverage, and Court Decisions Its election season and drug pricing issues are once again front and center in the policy wars on managing the high cost of healthcare. mark for My Articles similar articles
Pharmaceutical Executive
August 1, 2005
Sarah Houlton
Global Report: Big Disadvantage Is the European Commission's definition of market dominance too narrow? AstraZeneca thinks so. mark for My Articles similar articles
The Motley Fool
October 30, 2006
Brian Lawler
Sales Slow Down for Bristol-Myers Plavix isn't the only drug facing a challenging future. Losing patent protection and facing generic competition can be disastrous to sales and earnings if a pharmaceutical company doesn't have a way to drive revenue growth. Investors, take note. mark for My Articles similar articles
The Motley Fool
September 12, 2005
M.D. Mitchell
Big Problems for Big Pharma Creating new drugs is never easy, but the companies that excel in three key areas are the ones for investors to watch. mark for My Articles similar articles
The Motley Fool
August 6, 2011
Sean Williams
10 Large Caps to Rule Them All There's nothing generic about this company. For the inaugural large-cap pick, I think we should revisit pharma's most impervious pipeline, Teva Pharmaceuticals. mark for My Articles similar articles
Pharmaceutical Executive
October 1, 2010
Taking a Less-Generic Route to Generics A leading pharmaceutical industry player speaks out on what is fueling success in the sector. mark for My Articles similar articles
Pharmaceutical Executive
October 1, 2005
Glass & Worrell
Whose Afraid of Authorized Generics Losing a patent challenge lets a generic competitor grab market share and slash branded profits. Sound scary? Ignoring authorized generics is worse. mark for My Articles similar articles
The Motley Fool
May 31, 2007
Brian Lawler
Dueling Fools: Eli Lilly Bear Well-managed companies don't always make for good investments. This pharmaceutical powerhouse is a good example. mark for My Articles similar articles
The Motley Fool
January 31, 2007
Brian Lawler
You're Only Hurting Yourself, Thailand Thailand's decision to allow generics could do more harm than good. Investors, take note. mark for My Articles similar articles
The Motley Fool
May 21, 2009
Brian Orelli
If You Can't Beat 'Em, Join 'Em: Pharma Goes Generic In the battle against generic rivals, it seems pharmaceutical companies would rather switch than fight. A pair of deals heralds Big Pharma's latest moves into the generic-drug world. See what Novartis and sanofi-aventis recently did. mark for My Articles similar articles
Pharmaceutical Executive
October 1, 2006
Joanna Breitstein
"I Pray for the Welfare of Your Company..." Big Pharma's drugs fill Teva Pharmaceutical's pipeline. CEO Israel Makov says he's not the enemy. To prove it, he offers lessons in survival. mark for My Articles similar articles